Literature DB >> 22722783

Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations.

Yasushi Yatabe, William Pao, James R Jett.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22722783     DOI： 10.1097/JTO.0b013e318251980b

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  10 in total

1.  Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.

Authors:  M Beau-Faller; N Prim; A-M Ruppert; I Nanni-Metéllus; R Lacave; L Lacroix; F Escande; S Lizard; J-L Pretet; I Rouquette; P de Crémoux; J Solassol; F de Fraipont; I Bièche; A Cayre; E Favre-Guillevin; P Tomasini; M Wislez; B Besse; M Legrain; A-C Voegeli; L Baudrin; F Morin; G Zalcman; E Quoix; H Blons; J Cadranel
Journal:  Ann Oncol       Date:  2013-11-26       Impact factor: 32.976

2.  Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.

Authors:  Geoffrey R Oxnard; Peter C Lo; Mizuki Nishino; Suzanne E Dahlberg; Neal I Lindeman; Mohit Butaney; David M Jackman; Bruce E Johnson; Pasi A Jänne
Journal:  J Thorac Oncol       Date:  2013-02       Impact factor: 15.609

3.  Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.

Authors:  Susumu Kobayashi; Hannah M Canepa; Alexandra S Bailey; Sohei Nakayama; Norihiro Yamaguchi; Michael A Goldstein; Mark S Huberman; Daniel B Costa
Journal:  J Thorac Oncol       Date:  2013-01       Impact factor: 15.609

4.  BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.

Authors:  Svetlana A Protsenko; Anna I Semionova; Yuri I Komarov; Svetlana N Aleksakhina; Alexandr O Ivantsov; Aglaya G Iyevleva; Evgeny N Imyanitov
Journal:  Invest New Drugs       Date:  2015-08-20       Impact factor: 3.850

5.  DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.

Authors:  Paul Yeh; Heidi Chen; Jenny Andrews; Riyad Naser; William Pao; Leora Horn
Journal:  Clin Cancer Res       Date:  2013-01-23       Impact factor: 12.531

6.  EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.

Authors:  Allison Ackerman; Michael A Goldstein; Susumu Kobayashi; Daniel B Costa
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

Review 7.  Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.

Authors:  Tianhong Li; Hsing-Jien Kung; Philip C Mack; David R Gandara
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544

8.  Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations.

Authors:  Liang Peng; Zhi-Gang Song; Shun-Chang Jiao
Journal:  Sci Rep       Date:  2014-08-18       Impact factor: 4.379

9.  Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing.

Authors:  Luisella Righi; Alessandra Cuccurullo; Simona Vatrano; Susanna Cappia; Daniela Giachino; Paolo De Giuli; Mara Ardine; Silvia Novello; Marco Volante; Giorgio V Scagliotti; Mauro Papotti
Journal:  BMC Cancer       Date:  2013-03-13       Impact factor: 4.430

10.  Brain metastasis in non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations: a report of seven cases and literature review.

Authors:  Puchun Er; Tian Zhang; Jing Wang; Qingsong Pang; Ping Wang
Journal:  Cancer Biol Med       Date:  2017-11       Impact factor: 4.248
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.